Studies

27 studies · Download as JSON

• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 3 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2026-06-16Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
• Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesRandomized trial · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-12Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-09Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-08-05Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-05-03Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc AnalysisRandomized trial · 2023 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitusCell / in-vitro · 2022 · Study tier 4 · Not human evidence · Unclear · Unreviewed automatic assessment
• The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysisClinical trial · 2022 · Study tier 4 · Different population · Null · Unreviewed automatic assessment
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialRandomized trial · 2019 · Study tier 1 · Different population · Benefit · Industry funded
• The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes MellitusRandomized trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-UpRandomized trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysisMeta-analysis · 2016 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment